AIM ImmunoTech

Voir l'organigramme avec ses 8 principaux dirigeants

Biographies les plus recherchées chez AIM ImmunoTech

• Thomas Equels, Executive Vice Chairman, Chief Executive Officer a...
• Nancy Bryan, Director
• William Mitchell, Chairman of the Board

Créer une alerte
pour suivre les mouvements de dirigeants chez AIM ImmunoTech.

AIM ImmunoTech a 2 274 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Adaptive Phage Therapeutics (Etats—Unis).

Actualités en fusion/acquisition en Biotechnologie.

• Bruker has announced the acquisition of NanoString Technologies  (publié le 18 avril 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publié le 16 avril 2024).
• Nurix Therapeutics vient d'annoncer une levée de fonds de 175 millions de dollars. (publié le 13 avril 2024).

Contacts en Biotechnologie

• Vik Bajaj - Director chez Interline Therapeutics
• Ali Behbahani - Non-Executive Director chez Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board chez Sensorion

En savoir plus sur le secteur Biotechnologie >

Derniers communiqués de presse par AIM ImmunoTech

• Press Releases | AIM Immunotech
• AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - AIM ImmunoTech Inc.
• AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
• AIM ImmunoTech Issues Letter to Stockholders - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - AIM ImmunoTech Inc.
• AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?" - AIM ImmunoTech Inc.
• AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - AIM ImmunoTech Inc.
• AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - AIM ImmunoTech Inc.
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de AIM ImmunoTech

• AIM ImmunoTech sur Wikipédia, Google News & Yahoo Finance en 1-click
• AIM ImmunoTech sur LinkedIn, Twitter & YouTube en 1-click

Contacter par email ses dirigeants dont Thomas Equels

Appelez AIM ImmunoTech au +1 212...

Voir l'organigramme

S'inscrire pour recevoir votre alerte

Signaler une erreur